Product
VERVE-102
1 clinical trial
2 indications
Indication
Coronary Heart DiseaseClinical trial
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein CholesterolStatus: Not yet recruiting, Estimated PCD: 2026-08-01